{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:59:57Z","timestamp":1791197997906,"version":"4.1.0"},"reference-count":141,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Immunotherapy has revolutionized the treatment of multiple myeloma (MM), but durable immune control remains limited, increasing interest in how the bone marrow (BM) microenvironment influences antitumor immunity. BM adipocytes (BMAds) are increasingly recognized as metabolically active components of the BM. This review summarizes the current evidence linking BMAds to myeloma cell survival and immune cell function, particularly T cell activity. It also discusses their potential relevance to monoclonal antibodies, bispecific antibodies, and chimeric antigen receptor (CAR) T-cell therapy. Preclinical studies have shown that myeloma-associated BMAds undergo lipid depletion and acquire inflammatory and senescence-associated secretory features. BM lipid exposure is associated with impaired CD8+ T-cell metabolic fitness, whereas leptin receptor activation suppresses invariant natural killer T-cell anti-myeloma activity. Evidence concerning conventional natural killer cells and other immune compartments remains limited. Available clinical evidence is predominantly cross-sectional and therefore does not establish a direct role for BMAds in resistance to current immunotherapies or clarify whether they influence therapeutic target availability or function as clinically relevant bystander targets. Patient- and treatment-related factors, including aging and obesity, may further reshape the adipocytic-stromal and immune landscape of the marrow, potentially modifying local responses to immunotherapy. Future studies combining patient-derived multicellular models with spatial and longitudinal approaches should determine how BMAd-associated metabolic, inflammatory, and adipokine signaling affect immune control and treatment outcomes in MM and whether these processes can be therapeutically modulated.<\/jats:p>","DOI":"10.3390\/cancers18193213","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:02:27Z","timestamp":1791194547000},"page":"3213","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bone Marrow Adipocytes in Multiple Myeloma: Emerging Immunometabolic Interactions and Implications for Immunotherapy"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4194-9119","authenticated-orcid":false,"given":"Adriana","family":"Roque","sequence":"first","affiliation":[{"name":"Clinical Hematology Unit, Unidade Local de Sa\u00fade de Coimbra (ULS Coimbra), 3004-561 Coimbra, Portugal"},{"name":"Institute of Physiology, Faculty of Medicine, University of Coimbra (FMUC), 3000-548 Coimbra, Portugal"},{"name":"University Clinics of Hematology and Oncology and Laboratory of Oncobiology and Hematology, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Paiva","sequence":"additional","affiliation":[{"name":"Unidade Funcional de Citometria de Fluxo, ULS Coimbra, 3004-561 Coimbra, Portugal"},{"name":"Faculty of Medicine, Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, 3000-548 Coimbra, Portugal"},{"name":"Ci\u00eancias Biom\u00e9dicas Laboratoriais, ESTESC-Coimbra Health School, Instituto Polit\u00e9cnico de Coimbra, 3045-043 Coimbra, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8378-0895","authenticated-orcid":false,"given":"Raquel","family":"Sei\u00e7a","sequence":"additional","affiliation":[{"name":"Institute of Physiology, Faculty of Medicine, University of Coimbra (FMUC), 3000-548 Coimbra, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catarina","family":"Geraldes","sequence":"additional","affiliation":[{"name":"Clinical Hematology Unit, Unidade Local de Sa\u00fade de Coimbra (ULS Coimbra), 3004-561 Coimbra, Portugal"},{"name":"University Clinics of Hematology and Oncology and Laboratory of Oncobiology and Hematology, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal"},{"name":"Faculty of Medicine, Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, 3000-548 Coimbra, Portugal"},{"name":"Group of Environmental Genetics of Oncobiology (CIMAGO), Faculty of Medicine, University of Coimbra (FMUC), 3004-504 Coimbra, Portugal"},{"name":"Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, 3004-504 Coimbra, Portugal"},{"name":"Clinical Academic Center of Coimbra (CACC), 3000-076 Coimbra, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Iannozzi, N.T., Giuliani, N., and Storti, P. (2025). Deciphering the bone marrow microenvironment\u2019s role in multiple myeloma immunotherapy resistance. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1613265"},{"key":"ref_3","first-page":"337","article-title":"Monoclonal Antibodies in the Treatment of Multiple Myeloma","volume":"38","author":"Zweegman","year":"2023","journal-title":"Hematol. Clin. N. Am."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/14737140.2024.2344647","article-title":"Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma","volume":"24","author":"Tacchetti","year":"2024","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1182\/blood-2023-178534","article-title":"Comprehensive Characterization of the Bone Marrow Microenvironment Transcriptional Remodeling in the Progression from MGUS to Smoldering and Multiple Myeloma","volume":"142","author":"Cenzano","year":"2023","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Danziger, S.A., McConnell, M., Gockley, J., Young, M.H., Rosenthal, A., Schmitz, F., Reiss, D.J., Farmer, P., Alapat, D.V., and Singh, A. (2020). Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials. PLoS Med., 17, Erratum in PLoS Med. 2021, 18, e1003774. https:\/\/doi.org\/10.1371\/journal.pmed.1003774.","DOI":"10.1371\/journal.pmed.1003774"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s43018-025-01072-4","article-title":"A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma","volume":"7","author":"Pilcher","year":"2026","journal-title":"Nat. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Falank, C., Fairfield, H., and Reagan, M.R. (2016). Signaling Interplay between Bone Marrow Adipose Tissue and Multiple Myeloma cells. Front. Endocrinol., 7.","DOI":"10.3389\/fendo.2016.00067"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"9159","DOI":"10.1002\/jcp.26884","article-title":"Adipokines, adiposity, and bone marrow adipocytes: Dangerous accomplices in multiple myeloma","volume":"233","author":"Morris","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1023\/A:1011513223894","article-title":"Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis","volume":"2","author":"Justesen","year":"2001","journal-title":"Biogerontology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s11357-022-00698-x","article-title":"Multiple myeloma, a quintessential malignant disease of aging: A geroscience perspective on pathogenesis and treatment","volume":"45","author":"Urban","year":"2022","journal-title":"GeroScience"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"8332","DOI":"10.1038\/s41467-025-63395-1","article-title":"Clinical implications of bone marrow adiposity identified by phenome-wide association and Mendelian randomization in the UK Biobank","volume":"16","author":"Xu","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/sj.leu.2404658","article-title":"Neighboring adipocytes participate in the bone marrow microenvironment of multiple myeloma cells","volume":"21","author":"Caers","year":"2007","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.canlet.2016.06.010","article-title":"Adipocytes contribute to the growth and progression of multiple myeloma: Unraveling obesity related differences in adipocyte signaling","volume":"380","author":"Bullwinkle","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"34329","DOI":"10.18632\/oncotarget.6020","article-title":"Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation","volume":"6","author":"Liu","year":"2015","journal-title":"Oncotarget"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1182\/blood.2021013832","article-title":"Multiple myeloma cells induce lipolysis in adipocytes and uptake fatty acids through fatty acid transporter proteins","volume":"139","author":"Panaroni","year":"2022","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"7808","DOI":"10.1038\/ncomms8808","article-title":"Region-specific variation in the properties of skeletal adipocytes reveals regulated and constitutive marrow adipose tissues","volume":"6","author":"Scheller","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.coph.2016.03.001","article-title":"Bone marrow adipose tissue: Formation, function and regulation","volume":"28","author":"Suchacki","year":"2016","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Bravenboer, N., Bredella, M.A., Chauveau, C., Corsi, A., Douni, E., Ferris, W.F., Riminucci, M., Robey, P.G., Rojas-Sutterlin, S., and Rosen, C. (2020). Standardised Nomenclature, Abbreviations, and Units for the Study of Bone Marrow Adiposity: Report of the Nomenclature Working Group of the International Bone Marrow Adiposity Society. Front. Endocrinol., 10.","DOI":"10.3389\/fendo.2019.00923"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"eaay8203","DOI":"10.1126\/scisignal.aay8203","article-title":"Myeloma cells shift osteoblastogenesis to adipogenesis by inhibiting the ubiquitin ligase MURF1 in mesenchymal stem cells","volume":"13","author":"Liu","year":"2020","journal-title":"Sci. Signal."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"eaau9087","DOI":"10.1126\/scitranslmed.aau9087","article-title":"Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease","volume":"11","author":"Liu","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Fairfield, H., Costa, S., Falank, C., Farrell, M., Murphy, C.S., D\u2019aMico, A., Driscoll, H., and Reagan, M.R. (2021). Multiple Myeloma Cells Alter Adipogenesis, Increase Senescence-Related and Inflammatory Gene Transcript Expression, and Alter Metabolism in Preadipocytes. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.584683"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"101856","DOI":"10.1016\/j.tranon.2023.101856","article-title":"Bone marrow adipocytes is a new player in supporting myeloma cells proliferation and survival in myeloma microenvironment","volume":"40","author":"Wei","year":"2023","journal-title":"Transl. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1038\/bcj.2011.22","article-title":"Myeloma cells suppress osteoblasts through sclerostin secretion","volume":"1","author":"Colucci","year":"2011","journal-title":"Blood Cancer J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/jcp.25976","article-title":"The skeletal cell-derived molecule sclerostin drives bone marrow adipogenesis","volume":"233","author":"Fairfield","year":"2017","journal-title":"J. Cell. Physiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1182\/blood-2017-03-773341","article-title":"Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma","volume":"129","author":"McDonald","year":"2017","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/s41392-025-02455-w","article-title":"Piezo1 activation suppresses bone marrow adipogenesis to prevent osteoporosis by inhibiting a mechanoinflammatory autocrine loop","volume":"10","author":"Wang","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/jbmr.4282","article-title":"Intercellular Interactions of an Adipogenic CXCL12-Expressing Stromal Cell Subset in Murine Bone Marrow","volume":"36","author":"Matsushita","year":"2021","journal-title":"J. Bone Miner. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e66275","DOI":"10.7554\/eLife.66275","article-title":"A bone-specific adipogenesis pathway in fat-free mice defines key origins and adaptations of bone marrow adipocytes with age and disease","volume":"10","author":"Zhang","year":"2021","journal-title":"eLife"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e54695","DOI":"10.7554\/eLife.54695","article-title":"Single cell transcriptomics identifies a unique adipose lineage cell population that regulates bone marrow environment","volume":"9","author":"Zhong","year":"2020","journal-title":"eLife"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40164-025-00606-x","article-title":"A proinflammatory response and polarized differentiation of stromal elements characterizes the murine myeloma bone marrow niche","volume":"14","author":"Ghamlouch","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/bjh.15669","article-title":"Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes","volume":"184","author":"Mehdi","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.celrep.2019.12.089","article-title":"Human Bone Marrow Is Comprised of Adipocytes with Specific Lipid Metabolism","volume":"30","author":"Chaoui","year":"2020","journal-title":"Cell Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ebiom.2019.07.023","article-title":"Human bone marrow adipocytes display distinct immune regulatory properties","volume":"46","author":"Miggitsch","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/s42003-025-08975-z","article-title":"Characterization of the bone marrow architecture of multiple myeloma using spatial transcriptomics","volume":"8","author":"Sudupe","year":"2025","journal-title":"Commun. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.bone.2018.03.011","article-title":"Bone marrow adiposity and multiple myeloma","volume":"118","author":"Morris","year":"2019","journal-title":"Bone"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Rasch, S., Lund, T., Asmussen, J.T., Nielsen, A.L., Larsen, R.F., Andersen, M.\u00d8., and Abildgaard, N. (2020). Multiple Myeloma Associated Bone Disease. Cancers, 12.","DOI":"10.20944\/preprints202007.0041.v1"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1016\/j.ajpath.2016.07.012","article-title":"Adipocyte-Lineage Cells Support Growth and Dissemination of Multiple Myeloma in Bone","volume":"186","author":"Trotter","year":"2016","journal-title":"Am. J. Pathol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Fairfield, H., Condruti, R., Farrell, M., Di Iorio, R., Gartner, C.A., Vary, C., and Reagan, M.R. (2023). Development and characterization of three cell culture systems to investigate the relationship between primary bone marrow adipocytes and myeloma cells. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.912834"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"101861","DOI":"10.1016\/j.bonr.2025.101861","article-title":"Experimental analysis of bone marrow adipose tissue and bone marrow adipocytes: An update from the bone marrow adiposity society (BMAS)","volume":"26","author":"Tencerova","year":"2025","journal-title":"Bone Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"6035","DOI":"10.1182\/bloodadvances.2023009890","article-title":"Uptake of long-chain fatty acids from the bone marrow suppresses CD8+ T-cell metabolism and function in multiple myeloma","volume":"7","author":"Gudgeon","year":"2023","journal-title":"Blood Adv."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1038\/leu.2017.146","article-title":"Leptin receptor antagonism of iNKT cell function: A novel strategy to combat multiple myeloma","volume":"31","author":"Favreau","year":"2017","journal-title":"Leukemia"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1158\/0008-5472.CAN-20-1088","article-title":"Myeloma-Modified Adipocytes Exhibit Metabolic Dysfunction and a Senescence-Associated Secretory Phenotype","volume":"81","author":"Fairfield","year":"2020","journal-title":"Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Kwak, J.-G., and Lee, J. (2023). Bone Marrow Adipocytes Contribute to Tumor Microenvironment-Driven Chemoresistance via Sequestration of Doxorubicin. Cancers, 15.","DOI":"10.3390\/cancers15102737"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"6819","DOI":"10.1182\/blood-2024-207970","article-title":"Soluble Signals Exchanged between Bone Marrow Adipocytes and Myeloma Cells Alter the Expression of Metabolic Genes in Adipocytes and Increase Pro-Survival Molecules in Myeloma Cells","volume":"144","author":"Fairfield","year":"2024","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"20","DOI":"10.18632\/oncotarget.28548","article-title":"Bone marrow adipocytes provide early sign for progression from MGUS to multiple myeloma","volume":"15","author":"Leka","year":"2024","journal-title":"Oncotarget"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.1182\/blood-2025-7462","article-title":"Bone marrow adipose tissue is enriched in multiple myeloma cells","volume":"146","author":"Ernszt","year":"2025","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1007\/s00330-017-4907-8","article-title":"Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction","volume":"27","author":"Latifoltojar","year":"2017","journal-title":"Eur. Radiol."},{"key":"ref_49","unstructured":"Martel, D., Bruno, M., and Mayerhoefer, M. (2025, January 10\u201315). Characterizing Bone Marrow Adipose Tissue Composition in Multiple Myeloma Using Chemical Shift Encoded MRI. Proceedings of the 2025 ISMRM & ISMRT Annual Meeting & Exhibition, Honolulu, HI, USA."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6991","DOI":"10.1182\/blood-2024-207416","article-title":"Vertebral Fat Fraction (FF) Quantified By Magnetic Resonance Imaging for Assessing Prognosis and Therapeutic Response in Multiple Myeloma","volume":"144","author":"Wang","year":"2024","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"86075","DOI":"10.18632\/oncotarget.13342","article-title":"Adipocytes secreted leptin is a pro-tumor factor for survival of multiple myeloma under chemotherapy","volume":"7","author":"Yu","year":"2016","journal-title":"Oncotarget"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/jbmr.3951","article-title":"Myeloma Cells Down-Regulate Adiponectin in Bone Marrow Adipocytes Via TNF-Alpha","volume":"35","author":"Morris","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"5872","DOI":"10.1182\/blood-2011-01-330407","article-title":"Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease","volume":"118","author":"Fowler","year":"2011","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1182\/blood-2021-150208","article-title":"Bone Marrow Adipocyte Shapes Metabolism and Immunity in Tumor Microenvironment to Promote Multiple Myeloma","volume":"138","author":"Shu","year":"2021","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13046-021-02209-w","article-title":"Induction of m6A methylation in adipocyte exosomal LncRNAs mediates myeloma drug resistance","volume":"41","author":"Wang","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_56","first-page":"193","article-title":"Low circulating adiponectin and resistin, but not leptin, levels are associated with multiple myeloma risk: A case\u2013control study","volume":"20","author":"Dalamaga","year":"2008","journal-title":"Cancer Causes Control"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1600-0609.2009.01311.x","article-title":"Abnormal adipokine levels and leptin-induced changes in gene expression profiles in multiple myeloma","volume":"83","author":"Reseland","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5958","DOI":"10.4049\/jimmunol.176.10.5958","article-title":"Adiponectin Is a Negative Regulator of NK Cell Cytotoxicity","volume":"176","author":"Kim","year":"2006","journal-title":"J. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1158\/0008-5472.CAN-13-1397","article-title":"Adiponectin Receptor Signaling on Dendritic Cells Blunts Antitumor Immunity","volume":"74","author":"Tan","year":"2014","journal-title":"Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.immuni.2016.05.010","article-title":"Adiponectin Enhances Antibacterial Activity of Hematopoietic Cells by Suppressing Bone Marrow Inflammation","volume":"44","author":"Masamoto","year":"2016","journal-title":"Immunity"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3324\/haematol.2016.154062","article-title":"Resistin induces multidrug resistance in myeloma by inhibiting cell death and upregulating ABC transporter expression","volume":"102","author":"Pang","year":"2017","journal-title":"Haematologica"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40364-018-0134-y","article-title":"Chemerin is elevated in multiple myeloma patients and is expressed by stromal cells and pre-adipocytes","volume":"6","author":"Westhrin","year":"2018","journal-title":"Biomark. Res."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Al-Ali, N.O., Csige, D., Pincz\u00e9s, L.I., Farkas, K., Rebenku, I., Domj\u00e1n, A., Panyi, G., Szekanecz, Z., Sz\u0171cs, G., and Ill\u00e9s, \u00c1. (2025). Adipokines as Prognostic Biomarkers in Multiple Myeloma: A Case\u2013Control Study. Medicina, 61.","DOI":"10.3390\/medicina61112065"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Diedrich, J.D., Cole, C.E., Pianko, M.J., Colacino, J.A., and Bernard, J.J. (2023). Non-Toxicological Role of Aryl Hydrocarbon Receptor in Obesity-Associated Multiple Myeloma Cell Growth and Survival. Cancers, 15.","DOI":"10.3390\/cancers15215255"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"100229","DOI":"10.1016\/j.bneo.2026.100229","article-title":"Microenvironmentally derived fatty acid\u2013binding proteins 4 and 5 are novel therapeutic vulnerabilities in multiple myeloma","volume":"3","author":"Duval","year":"2026","journal-title":"Blood Neoplasia"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e81184","DOI":"10.7554\/eLife.81184","article-title":"Targeting the fatty acid binding proteins disrupts multiple myeloma cell cycle progression and MYC signaling","volume":"12","author":"Farrell","year":"2023","journal-title":"eLife"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1182\/blood-2021-149191","article-title":"Multiple Myeloma Derived Mitochondrial Damps Induce Inflammation in the Bone Marrow Adipose Tissue Which Promotes Tumour Development","volume":"138","author":"Jibril","year":"2021","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/cei.13594","article-title":"Bone marrow-derived mesenchymal stem cells inhibit CD8+ T cell immune responses via PD-1\/PD-L1 pathway in multiple myeloma","volume":"205","author":"Liu","year":"2021","journal-title":"Clin. Exp. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"52614","DOI":"10.18632\/oncotarget.17538","article-title":"MM-BMSCs induce na\u00efve CD4+ T lymphocytes dysfunction through fibroblast activation protein \u03b1","volume":"8","author":"Wu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_70","first-page":"213","article-title":"Immune impairments in multiple myeloma bone marrow mesenchymal stromal cells","volume":"64","author":"Najar","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Cooke, R.E., Quinn, K.M., Quach, H., Harrison, S., Prince, H.M., Koldej, R., and Ritchie, D. (2020). Conventional Treatment for Multiple Myeloma Drives Premature Aging Phenotypes and Metabolic Dysfunction in T Cells. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.02153"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1038\/leu.2016.84","article-title":"Multiple myeloma causes clonal T-cell immunosenescence: Identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade","volume":"30","author":"Suen","year":"2016","journal-title":"Leukemia"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1182\/blood-2024-208837","article-title":"Single-Cell RNA-Sequencing of 6 Million Tumor and Immune Cells in 365 Patients with MGUS and SMM Demonstrates Complex Progressive Changes in Immune Cell Functionality with a Distinct Footprint on Tumor Cell Biology and Disease Control","volume":"144","author":"Wu","year":"2024","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e561","DOI":"10.1097\/HS9.0000000000000561","article-title":"Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant","volume":"5","author":"Holthof","year":"2021","journal-title":"HemaSphere"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e861","DOI":"10.1002\/ctm2.861","article-title":"CD155\/TIGIT signalling plays a vital role in the regulation of bone marrow mesenchymal stem cell\u2013induced natural killer\u2013cell exhaustion in multiple myeloma","volume":"12","author":"Liu","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1182\/bloodadvances.2017012732","article-title":"Changes in bone marrow innate lymphoid cell subsets in monoclonal gammopathy: Target for IMiD therapy","volume":"1","author":"Bailur","year":"2017","journal-title":"Blood Adv."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Drommi, F., Calabr\u00f2, A., Pezzino, G., Vento, G., Freni, J., Costa, G., Cavaliere, R., Bonaccorsi, I., Allegra, A., and Ferlazzo, G. (2025). Multiple Myeloma Cells Shift the Fate of Cytolytic ILC2s Towards TIGIT-Mediated Cell Death. Cancers, 17.","DOI":"10.3390\/cancers17020263"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12935-018-0687-8","article-title":"Increased activated regulatory T cell subsets and aging Treg-like cells in multiple myeloma and monoclonal gammopathy of undetermined significance: A case control study","volume":"18","author":"Wang","year":"2018","journal-title":"Cancer Cell Int."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"43992","DOI":"10.18632\/oncotarget.6083","article-title":"The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/s41419-019-2012-4","article-title":"CCL2 promotes macrophages-associated chemoresistance via MCPIP1 dual catalytic activities in multiple myeloma","volume":"10","author":"Xu","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1038\/s41375-024-02391-8","article-title":"IL-10R inhibition reprograms tumor-associated macrophages and reverses drug resistance in multiple myeloma","volume":"38","author":"Sun","year":"2024","journal-title":"Leukemia"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1182\/blood-2015-01-623975","article-title":"Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing","volume":"126","author":"Leone","year":"2015","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Lv, J., Sun, H., Gong, L., Wei, X., He, Y., Yu, Z., Liu, L., Yi, S., Sui, W., and Xu, Y. (2022). Aberrant metabolic processes promote the immunosuppressive microenvironment in multiple myeloma. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1077768"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41375-024-02482-6","article-title":"International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma","volume":"39","author":"Costa","year":"2025","journal-title":"Leukemia"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1186\/s12964-025-02443-1","article-title":"CAR-NK cell therapy in multiple myeloma: From preclinical and clinical landscape to joining the force for treatment strategies optimization","volume":"23","author":"Yazdanparast","year":"2025","journal-title":"Cell Commun. Signal."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood.2023022823","article-title":"Correlation of immune fitness with response to teclistamab in relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"144","author":"Perova","year":"2024","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/ejh.70168","article-title":"The Role of Microenvironment in Bispecific Antibodies Treatment in Multiple Myeloma","volume":"117","author":"Barachini","year":"2026","journal-title":"Eur. J. Haematol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/ijo.2017.140","article-title":"Identification of the ectoenzyme CD38 as a marker of committed preadipocytes","volume":"41","author":"Jeanson","year":"2017","journal-title":"Int. J. Obes."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1158\/1078-0432.CCR-18-1597","article-title":"The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma","volume":"25","author":"Moreno","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e1339853","DOI":"10.1080\/2162402X.2017.1339853","article-title":"The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and \u2013independent mechanisms","volume":"6","author":"Pazina","year":"2017","journal-title":"OncoImmunology"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3858\/emm.2009.41.3.024","article-title":"B cell activation factor (BAFF) is a novel adipokine that links obesity and inflammation","volume":"41","author":"Kim","year":"2009","journal-title":"Exp. Mol. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"5948","DOI":"10.4049\/jimmunol.0901186","article-title":"Adipocytes as Immune Cells: Differential Expression of TWEAK, BAFF, and APRIL and Their Receptors (Fn14, BAFF-R, TACI, and BCMA) at Different Stages of Normal and Pathological Adipose Tissue Development","volume":"183","author":"Alexaki","year":"2009","journal-title":"J. Immunol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood-2003-06-1984","article-title":"BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone","volume":"103","author":"Moreaux","year":"2004","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell\u2013Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-Targeted CAR T Cells for Myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood-2024-199542","article-title":"Cevostamab in Patients with Heavily Pretreated Relapsed\/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies","volume":"144","author":"Richter","year":"2024","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1182\/blood.2025028896","article-title":"Profiling the spatial architecture of multiple myeloma in human bone marrow trephine biopsy specimens with spatial transcriptomics","volume":"146","author":"Yip","year":"2025","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1016\/j.cell.2024.04.013","article-title":"Mapping the cellular biogeography of human bone marrow niches using single-cell transcriptomics and proteomic imaging","volume":"187","author":"Bandyopadhyay","year":"2024","journal-title":"Cell"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"111046","DOI":"10.1016\/j.celrep.2022.111046","article-title":"A human adipose tissue cell-type transcriptome atlas","volume":"40","author":"Struck","year":"2022","journal-title":"Cell Rep."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Benzi, A., Grozio, A., Spinelli, S., Sturla, L., Guse, A.H., De Flora, A., Zocchi, E., Heeren, J., and Bruzzone, S. (2021). Role of CD38 in Adipose Tissue: Tuning Coenzyme Availability. Nutrients, 13.","DOI":"10.3390\/nu13113734"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41408-024-01139-y","article-title":"Bispecific antibodies in the treatment of multiple myeloma","volume":"14","author":"Devasia","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Van De Donk, N.W.C.J., and Usmani, S.Z. (2018). CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02134"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Campbell, K.S., Cohen, A.D., and Pazina, T. (2018). Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02551"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","article-title":"International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Usmani","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/s41409-025-02787-9","article-title":"CAR T-cells in multiple myeloma: The race to the start line","volume":"61","author":"Bazarbachi","year":"2025","journal-title":"Bone Marrow Transplant."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/bloodadvances.2023011225","article-title":"CD8 effector T cells enhance teclistamab response in BCMA-exposed and -na\u00efve multiple myeloma","volume":"8","author":"Firestone","year":"2024","journal-title":"Blood Adv."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41413-026-00509-5","article-title":"Expansion of bone marrow adipocytes in obese mice leads to PD-L1-driven bone marrow immunosuppression and osteoclastogenesis","volume":"14","author":"Costa","year":"2026","journal-title":"Bone Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1158\/1078-0432.CCR-20-2188","article-title":"Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of Apoptosis","volume":"27","author":"Holthof","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1038\/s41375-025-02621-7","article-title":"Age-related mesenchymal stromal cell senescence is associated with progression from MGUS to multiple myeloma","volume":"39","author":"Plakhova","year":"2025","journal-title":"Leukemia"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e1465","DOI":"10.1210\/clinem\/dgad355","article-title":"The Multifaceted Roles of Bone Marrow Adipocytes in Bone and Hematopoietic Homeostasis","volume":"108","author":"Li","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1038\/s43587-025-00924-z","article-title":"Serum amyloid P secreted by bone marrow adipocytes drives skeletal amyloidosis","volume":"5","author":"Kumar","year":"2025","journal-title":"Nat. Aging"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1182\/blood.2025028587","article-title":"A T-cell\u2013based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapy","volume":"146","author":"Bruins","year":"2025","journal-title":"Blood"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s13679-025-00644-w","article-title":"Unraveling Obesity and Multiple Myeloma: Insights from Epidemiology and Molecular Mechanisms","volume":"14","author":"Manna","year":"2025","journal-title":"Curr. Obes. Rep."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.semcancer.2023.04.003","article-title":"Obesity and multiple myeloma: Emerging mechanisms and perspectives","volume":"92","author":"Tentolouris","year":"2023","journal-title":"Semin. Cancer Biol."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Marques-Mourlet, C., Di Iorio, R., Fairfield, H., and Reagan, M.R. (2023). Obesity and myeloma: Clinical and mechanistic contributions to disease progression. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1118691"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.stem.2017.02.009","article-title":"Adipocyte Accumulation in the Bone Marrow during Obesity and Aging Impairs Stem Cell-Based Hematopoietic and Bone Regeneration","volume":"20","author":"Ambrosi","year":"2017","journal-title":"Cell Stem Cell"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41467-024-55422-4","article-title":"Deep learning and genome-wide association meta-analyses of bone marrow adiposity in the UK Biobank","volume":"16","author":"Xu","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Ochiai, M., Fierstein, S., XsSali, F., DeVito, N., Purkey, L.R., May, R., Correa-Medina, A., Kelley, M., Page, T.D., and DeCicco-Skinner, K. (2023). Unlocking Drug Resistance in Multiple Myeloma: Adipocytes as Modulators of Treatment Response. Cancers, 15.","DOI":"10.3390\/cancers15174347"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1182\/blood-2024-208818","article-title":"Characterization of the Tumor Microenvironment of Diagnostic Bone Marrow Core Biopsies from African American Multiple Myeloma Patients Using Imaging Mass Cytometry","volume":"144","author":"Colombo","year":"2024","journal-title":"Blood"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hon.70096_781","article-title":"781 | Impact of Obesity and Overweight on Outcomes of Patients with B-Cell Lymphomas and Multiple Myeloma Treated with Car-T Cells: A Systematic Review and Meta-Analysis","volume":"43","author":"Roque","year":"2025","journal-title":"Hematol. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","article-title":"EHA\u2013EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma","volume":"22","author":"Dimopoulos","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e832","DOI":"10.1038\/cddis.2013.348","article-title":"Dexamethasone shifts bone marrow stromal cells from osteoblasts to adipocytes by C\/EBPalpha promoter methylation","volume":"4","author":"Li","year":"2013","journal-title":"Cell Death Dis."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.cmet.2023.03.005","article-title":"Oxylipin-PPAR\u03b3-initiated adipocyte senescence propagates secondary senescence in the bone marrow","volume":"35","author":"Liu","year":"2023","journal-title":"Cell Metab."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s002230020018","article-title":"Troglitazone Treatment Increases Bone Marrow Adipose Tissue Volume but Does not Affect Trabecular Bone Volume in Mice","volume":"69","author":"Tornvig","year":"2001","journal-title":"Calcif. Tissue Int."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Lu, W., Wang, W., Wang, S., Feng, Y., and Liu, K. (2016). Rosiglitazone Promotes Bone Marrow Adipogenesis to Impair Myelopoiesis under Stress. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0149543"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes (2026). 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026. Diabetes Care, 49, S183\u2013S215.","DOI":"10.2337\/dc26-S009"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"10396","DOI":"10.1038\/s41467-024-54543-0","article-title":"Multiple myeloma long-term survivors exhibit sustained immune alterations decades after first-line therapy","volume":"15","author":"Lutz","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"101598","DOI":"10.1016\/j.molmet.2022.101598","article-title":"Novel thiazolidinedione analog reduces a negative impact on bone and mesenchymal stem cell properties in obese mice compared to classical thiazolidinediones","volume":"65","author":"Benova","year":"2022","journal-title":"Mol. Metab."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.clim.2004.06.011","article-title":"Human multiple myeloma cells express peroxisome proliferator-activated receptor \u03b3 and undergo apoptosis upon exposure to PPAR\u03b3 ligands","volume":"113","author":"Ray","year":"2004","journal-title":"Clin. Immunol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/00001813-200411000-00004","article-title":"Ligands of peroxisome proliferator-activated receptor \u03b3 induce apoptosis in multiple myeloma","volume":"15","author":"Eucker","year":"2004","journal-title":"Anti-Cancer Drugs"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"215832","DOI":"10.1016\/j.canlet.2022.215832","article-title":"PPAR agonists attenuate lenalidomide\u2019s anti-myeloma activity in vitro and in vivo","volume":"545","author":"Sha","year":"2022","journal-title":"Cancer Lett."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"e69209","DOI":"10.7554\/eLife.69209","article-title":"Adipsin promotes bone marrow adiposity by priming mesenchymal stem cells","volume":"10","author":"Aaron","year":"2021","journal-title":"eLife"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1096\/fj.201800948RR","article-title":"Progenitor recruitment and adipogenic lipolysis contribute to the anabolic actions of parathyroid hormone on the skeleton","volume":"33","author":"Maridas","year":"2018","journal-title":"FASEB J."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Chougule, A., Baroi, S., Czernik, P.J., Crowe, E., Chang, M.R., Griffin, P.R., and Lecka-Czernik, B. (2023). Osteocytes contribute via nuclear receptor PPAR-alpha to maintenance of bone and systemic energy metabolism. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1145467"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1038\/s41388-021-01874-7","article-title":"Statins reduce castration-induced bone marrow adiposity and prostate cancer progression in bone","volume":"40","author":"Pan","year":"2021","journal-title":"Oncogene"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1093\/jbmr\/zjae118","article-title":"Evaluation of romosozumab\u2019s effects on bone marrow adiposity in postmenopausal osteoporotic women: Results from the FRAME bone biopsy sub-study","volume":"39","author":"Chavassieux","year":"2024","journal-title":"J. Bone Miner. Res."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1158\/2159-8290.CD-25-1101","article-title":"A High-Fiber, Plant-Based Diet in Myeloma Precursor Disorders: Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model","volume":"16","author":"Shah","year":"2025","journal-title":"Cancer Discov."},{"key":"ref_141","unstructured":"U.S. National Library of Medicine (2026, July 12). BEAM-MM\u2014\u03b2-Hydroxybutyrate-Enhanced Adaptive Immunity in Multiple Myeloma (BEAM-MM), Available online: https:\/\/clinicaltrials.gov\/study\/NCT07564219."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/19\/3213\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:16:22Z","timestamp":1791195382000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/19\/3213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":141,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["cancers18193213"],"URL":"https:\/\/doi.org\/10.3390\/cancers18193213","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]}}}